cladribine has been researched along with Chronic Progressive Multiple Sclerosis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bass, AD; Fox, EJ; Harlow, DE; Hayward, B; Katz, J; Lebson, LA; Miravalle, AA; Robertson, D; Sloane, JA | 1 |
| Gold, R; Hoffmann, O | 1 |
| Adams, A; Allen-Philbey, K; Baker, D; Dubuisson, N; Giovannoni, G; Gnanapavan, S; Malaspina, A; Mao, Z; Schmierer, K; Yildiz, O | 1 |
| Manouchehri, N; Stüve, O | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 1 |
| Schmidt, S | 1 |
| Comi, G; Filippi, M; Giacomotti, L; Iannucci, G; Rice, GP; Rovaris, M; Sormani, MP | 1 |
| Lublin, FD | 1 |
3 review(s) available for cladribine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
[Disease-modifying treatment of secondary progressive multiple sclerosis].
Topics: Cladribine; Disease Progression; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Animals; Azathioprine; Cladribine; Clinical Trials, Phase III as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Long-Term Care; Lymphopenia; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Pregnancy; Purine Nucleosides; Randomized Controlled Trials as Topic; Thrombocytopenia | 2010 |
Therapeutic approaches to secondary progressive multiple sclerosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Cladribine; Clinical Trials as Topic; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Methotrexate; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive | 2002 |
2 trial(s) available for cladribine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Topics: Administration, Oral; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Tablets | 2021 |
The effect of cladribine on T(1) 'black hole' changes in progressive MS.
Topics: Analysis of Variance; Brain; Cladribine; Double-Blind Method; Drug Administration Schedule; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Time Factors | 2000 |
3 other study(ies) available for cladribine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine.
Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Immunotherapy; Male; Multiple Sclerosis, Chronic Progressive; Neurofilament Proteins; Subcutaneous Absorption | 2018 |
Trials and therapies in secondary progressive MS, simplified.
Topics: Azetidines; Benzyl Compounds; Cladribine; Clinical Trials as Topic; Drug Approval; Humans; Immunosuppressive Agents; Multiple Sclerosis, Chronic Progressive; Treatment Outcome; United States | 2019 |
[Progress of therapy in patients with multiple sclerosis].
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Brain; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Rituximab; Sphingosine | 2010 |